IO Biotech, Inc. (IOBTQ): restructuring charge — IO Biotech explores strategic alternatives, cuts workforce, CMO departs, hires Raymond James

IO Biotech, Inc.

Retained Raymond James as exclusive financial advisor to assist in exploration of strategic alternatives.
Board approved restructuring plan; expects $2.4M-$2.6M in one-time charges in Q1 2026.
Chief Medical Officer Qasim Ahmad's employment will end effective Feb 15, 2026.
Company implementing significant global workforce reduction to reduce operating expenses.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

IO Biotech, Inc. announced a restructuring with charges of approximately $2.4 million to $2.6 million affecting globally.

Type: restructuring
Charge: approximately $2.4 million to $2.6 million
Affected area: globally

Exact text from the filing

As part of previously announced efforts by IO Biotech, Inc. (the “Company”) to reduce the Company’s operating expenses while the Company explores a range of strategic alternatives, the Board of Directors of the Company approved on January 21, 2026, a restructuring and workforce reduction plan (the “Plan”) which is expected to result in a significant reduction of the Company’s workforce globally. In connection with the implementation of the Plan, the Company expects to incur one-time charges and cash expenditures in a range of approximately $2.4 million to $2.6 million, primarily related to employee wages and severance payments, healthcare continuation, earned vacation time and related termination costs.

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

IO Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-031987

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.